Bluejay Diagnostics Q1 net loss unchanged

Bluejay Diagnostics

07/05/2026 21:43

Overview

U.S. medical diagnostics firm's Q1 net loss was unchanged from prior year

Company advanced enrollment in pivotal SYMON-II clinical study for Symphony IL-6 test

Manufacturing readiness activities for Symphony cartridges progressed after resolving technical issues

Outlook

Company did not provide specific financial or operational guidance for the current or future periods

Result Drivers

CLINICAL TRIAL PROGRESS - Co continued strong enrollment in pivotal SYMON-II study for Symphony IL-6 test

MANUFACTURING READINESS - Co resolved technical issues in Symphony cartridge manufacturing and advanced toward validation activities

REGULATORY PREPARATION - Co maintained focus on FDA regulatory strategy for Symphony IL-6, preparing for future 510(k) submission

Company press release: ID:nGNX64BHnj

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$1.90 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)